Table 2.
Risk of prostate cancer death by statin use before ADT in a cohort of prostate cancer patients treated with ADT.
| Risk of PCa death | |||
|---|---|---|---|
| Statin use before ADT | No of participants/PCa deaths | Age-adjusted | Multivariable adjusted* |
| None | 2 904/593 | Reference | Reference |
| Any | 1 524/241 | 0.97 (0.84–1.13) | 1.12 (0.96–1.31) |
| Intensity of statin use | |||
| First tertile (below 120 DDD/year) | 508/82 | 0.90 (0.71–1.13) | 1.09 (0.86–1.38) |
| Second tertile (120–200 DDD/year) | 510/90 | 1.07 (0.86–1.34) | 1.19 (0.95–1.50) |
| Third tertile (above 200 DDD/year) | 506/69 | 0.94 (0.74–1.22) | 1.07 (0.83–1.38) |
*Calculated using Cox regression with adjustment for age, tumor risk group, randomization group, use of other medication (antidiabetic and antihypertensive drugs, NSAIDs), and whether participants received radiation therapy in addition to ADT.